Warfarin Titration After Stopping Rifampin
After stopping rifampin and switching to a non-hepatotoxic TB regimen (ethambutol, fluoroquinolone, streptomycin), you should anticipate reducing your warfarin dose by approximately 50-70% over 4 weeks, with the most aggressive reductions occurring in the first 2 weeks.
Immediate Management Strategy
Begin INR monitoring twice weekly for the first 2 weeks after rifampin discontinuation 1, 2. This is the highest-risk period for supratherapeutic INR and bleeding complications.
Week-by-Week Dose Reduction Protocol
Based on the strongest clinical evidence 1:
- Week 1: Reduce warfarin dose by 15-25%
- Week 2: Further reduce by an additional 15-25%
- Week 3: Reduce by another 20%
- Week 4: Final reduction of approximately 20%
Total expected dose reduction: 67% (range 58-70%) from your rifampin-stabilized dose 1.
Critical Monitoring Timeline
- Weeks 1-2: Check INR twice weekly (every 3-4 days)
- Weeks 3-4: Check INR weekly
- After week 4: Resume standard monitoring intervals once stable
Understanding the Mechanism
Rifampin is a potent CYP450 enzyme inducer that dramatically increases warfarin metabolism 3, 1. When you were on rifampin, you likely required 2-3 times your baseline warfarin dose to maintain therapeutic anticoagulation 1, 2, 4. The enzyme induction effect persists for up to 2 weeks after rifampin discontinuation 5, creating a dangerous window where warfarin accumulates as hepatic metabolism normalizes.
Specific Clinical Pitfalls
The most dangerous period is 3-4 weeks after stopping rifampin 2. One case documented an INR of 7.22 with macroscopic hematuria occurring 4 weeks post-rifampin discontinuation despite dose adjustments 2. This underscores that even with monitoring, the interaction offset is unpredictable.
Your New TB Regimen Considerations
Your switch to ethambutol, fluoroquinolone, and streptomycin eliminates the rifampin interaction but introduces new monitoring needs:
- Ethambutol: Check baseline visual acuity; monitor for optic neuritis 6, 7
- Streptomycin: Verify renal function before initiation; monitor for ototoxicity and nephrotoxicity 6, 7, 8
- Fluoroquinolone: No significant warfarin interaction, but monitor for QT prolongation
Alternative Approach: Rifabutin Consideration
If your TB treatment team is open to modification, rifabutin causes significantly less warfarin interaction than rifampin 9. One case achieved therapeutic INR with only an 18% warfarin dose increase (115 mg vs 140 mg weekly) after switching from rifampin to rifabutin 9. However, this decision must be made by your infectious disease specialist based on your TB susceptibility patterns.
Practical Dosing Example
If you were taking warfarin 10 mg daily while on rifampin:
- Week 1: Reduce to 7.5-8 mg daily
- Week 2: Reduce to 6-6.5 mg daily
- Week 3: Reduce to 5 mg daily
- Week 4: Reduce to 4 mg daily
- Target: Expect final stable dose around 3-3.5 mg daily (approximately your pre-rifampin dose)
Safety Monitoring
Hold warfarin and contact your anticoagulation clinic immediately if:
- INR >4.0 3
- Any bleeding (blood in urine, stool, excessive bruising)
- Severe headache or neurological symptoms
The warfarin-rifampin interaction offset requires more intensive monitoring than the onset phase 1, 2. Inter-patient variability is substantial, so these are guidelines—your actual requirements may differ. Pharmacist-managed anticoagulation clinics achieve better outcomes (56-93% time in therapeutic range vs 33-64% in usual care) 3, so consider this resource if available.